The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia

References

• Nutt R. The history of positron emission tomography. Mol. Imaging Biol.4(1), 11–26 (2002).
   PubMedGoogle Scholar
• Sokoloff L, Reivich M, Kennedy C et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem.28, 897–916 (1977).
   PubMed Web of Science ®Google Scholar
• Reivich M, Kuhl D, Wolf A et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ. Res.44, 127–137 (1979).
   PubMed Web of Science ®Google Scholar
• Schmidt KC, Lucignani G, Sokoloff L. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. J. Nucl. Med.37, 394–399 (1996).
   PubMedGoogle Scholar
• Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab.3, 1–7 (1983).
   PubMed Web of Science ®Google Scholar
• Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab.5, 584–590 (1985).
   PubMed Web of Science ®Google Scholar
• Oler JA, Fox AS, Shelton SE et al. Amygdalar and hippocampal substrates of anxious temperament differ in their heritability. Nature466(7308), 864–868 (2010).
   PubMed Web of Science ®Google Scholar
• Lee KJ, Lee JS, Kim SJ et al. Loss of asymmetry in D2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr. Scand.118(3), 200–208 (2008).
   PubMed Web of Science ®Google Scholar
• Erritzoe D, Rasmussen H, Kristiansen KT et al. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology33(10), 2435–2441 (2008).
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Takeuch K, Matsumoto T et al. Abnormal glucose metabolism in the anterior cingulate cortex in patients with schizophrenia. Psychiatry Res.154(1), 49–58 (2007).
   PubMed Web of Science ®Google Scholar
• Park IH, Kim JJ, Chun J et al. Medial prefrontal default-mode hypoactivity affecting trait physical anhedonia in schizophrenia. Psychiatry Res.171(3), 155–165 (2009).
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr. Bull.35(3), 549–562 (2009).
   PubMed Web of Science ®Google Scholar
• Vyas NS, Patel NH, Nijran KS, Al-Nahhas A, Puri BK. Can PET/CT imaging advance our understanding of the neurobiology of schizophrenia? Nucl. Med. Commun.31(2), 91–93 (2010).
   PubMedGoogle Scholar
• Nozaki S, Kato M, Takano H et al. Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET. Schizophr. Res.108(1–3), 78–84 (2009).
   PubMed Web of Science ®Google Scholar
• Kumakura Y, Cumming P, Vernaleken I et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J. Neurosci.27(30), 8080–8087 (2007).
   PubMed Web of Science ®Google Scholar
• Bose SK, Turkheimer FE, Howes OD et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr. Res.106(2–3), 148–155 (2008).
   PubMed Web of Science ®Google Scholar
• Catafau AM, Suarez M, Bullich S et al. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage46(2), 447–458 (2009).
   PubMedGoogle Scholar
• Howes OD, Egerton A, Allan V et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des.15(22), 2550–2559 (2009).
   PubMed Web of Science ®Google Scholar
• Hall H, Köhler C, Gawell L, Farde L, Sedvall G. Raclopride, a new selective ligand for the dopamine-D2 receptors. Prog. Neuro-Psychopharmacology Biol. Psy.12(5), 559–568 (1988).
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Christian BT, Lehrer DS et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res.85(1–3), 232–244 (2006).
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Buchsbaum BR, Hazlett EA et al. Relative glucose metabolic rate higher in white matter in patients with schizophrenia. Am. J. Psychiatry.164(7), 1072–1081 (2007).
   PubMed Web of Science ®Google Scholar
• van Berckel BN, Bossong MG, Boellaard R et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry64(9), 820–822 (2008).
   PubMed Web of Science ®Google Scholar
• Wilkerson A, Levin ED. Ventral hippocampal dopamine D1 and D2 systems and spatial working memory in rats. Neuroscience89(3), 743–749 (1999).
   PubMedGoogle Scholar
• Mizrahi R, Rusjan P, Agid O et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am. J. Psychiatry164(4), 630–637 (2007).
   PubMed Web of Science ®Google Scholar
• Reimold M, Solbach C, Noda S et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl).190(2), 241–249 (2007).
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Slifstein M, Frankle WG et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology33(13), 3111–3125 (2008).
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Haznedar M, Newmark RE et al. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophr. Res.114(1–3), 161–171 (2009).
   PubMed Web of Science ®Google Scholar
• Uchida H, Graff-Guerrero A, Mulsant BH, Pollock BG, Mamo DC. Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. Schizophr. Res.109(1–3), 130–133 (2009).
   PubMedGoogle Scholar
• Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am. J. Geriatr Psychiatry.17(3), 255–263 (2009).
   PubMed Web of Science ®Google Scholar
• Uchida H, Rajji TK, Mulsant BH et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J. Clin. Psychopharmacol.29(6), 571–575 (2009).
   PubMed Web of Science ®Google Scholar
• Horacek J, Brunovsky M, Novak T et al. Effect of low-frequency rTMS on electromagnetic tomography (LORETA) and regional brain metabolism (PET) in schizophrenia patients with auditory hallucinations. Neuropsychobiology55(3–4), 132–142 (2007).
   PubMed Web of Science ®Google Scholar
• Cho SS, Strafella AP. rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One4(8), e6725 (2009).
   PubMed Web of Science ®Google Scholar
• Rusjan PM, Barr MS, Farzan F et al. Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation. Hum. Brain Mapp.31(11), 1643–1652 (2010).
   PubMed Web of Science ®Google Scholar
• Erritzoe D, Rasmussen H, Kristiansen KT et al. Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology33(10), 2435–2441(2008).
   PubMed Web of Science ®Google Scholar
• Mamo D, Kapur S, Shammi CM et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry161(5), 818–825 (2004).
   PubMed Web of Science ®Google Scholar
• Frankle WG, Lombardo I, Kegeles LS et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl.)189(2), 155–164 (2006).
   PubMed Web of Science ®Google Scholar
• Dean B, Crossland N, Boer S, Scarr E. Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr. Res.104(1–3), 185–197 (2008).
   PubMed Web of Science ®Google Scholar
• Javitt DC. Glutamatergic theories of schizophrenia. Isr. J. Psychiatry Relat. Sci.47, 4–16 (2010).
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Leenders KL, Scharfetter C et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol.7(1), 9–24 (1997).
   PubMed Web of Science ®Google Scholar
• Mu L, Schubiger PA, Ametamey SM. Radioligands for the PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5). Curr. Top. Med. Chem.10(15), 1558–1568 (2010).
   PubMedGoogle Scholar
• Horti AG, Gao Y, Kuwabara H, Dannals RF. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci.86(15–16), 575–584 (2009).
   PubMedGoogle Scholar
• Toyohara J, Wu J, Hashimoto K. Recent development of radioligands for imaging α7 nicotinic acetylcholine receptors in the brain. Curr. Top Med. Chem.10(15), 1544–1557 (2010).
   PubMedGoogle Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology12(3), 426–445 (1998).
   PubMed Web of Science ®Google Scholar
• Dickinson D, Iannone VN, Wilk CM, Gold JM. General and specific cognitive deficits in schizophrenia. Biol. Psychiatry55(8), 826–833 (2004).
   PubMed Web of Science ®Google Scholar
• Rund BR, Melle I, Friis S et al. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am. J. Psychiatry161(3), 466–472 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar CTS, Christodoulou T, Vyas NS et al. Deficits in visual sustained attention differentiate genetic liability and disease expression for schizophrenia from bipolar disorder. Schizophr. Res.124(1–3), 152–160 (2010).
   PubMed Web of Science ®Google Scholar
• Vyas NS, Kumra S, Puri BK. What insights can we gain from studying early-onset schizophrenia? The neurodevelopmental pathway and beyond. Expert Rev. Neurother.10(8), 1243–1247 (2010).
   PubMed Web of Science ®Google Scholar
• Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J. Clin. Psychiatry67(S9), 3–8 (2006).
   PubMed Web of Science ®Google Scholar
• Vyas NS, Hadjulis M, Vourdas A, Byrne P, Frangou S. The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. Eur. Child. Adolesc. Psychiatry16(7), 465–470 (2007).
   PubMed Web of Science ®Google Scholar
• Leung WW, Bowie CR, Harvey PD. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study. J. Int. Neuropsychol. Soc.14(3), 479–488 (2008).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Mawlawi O, Lombardo I et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci.22(9), 3708–3719 (2002).
   PubMed Web of Science ®Google Scholar
• Patel NH, Vyas NS, Puri BK, Nijran KS, Al-Nahhas A. Positron emission tomography in schizophrenia: a new perspective. J. Nucl. Med.51(4), 510–520 (2010).
   Google Scholar
• Lee J, Folley BS, Gore J, Park S. Origins of spatial working memory deficits in schizophrenia: an event-related fMRI and near-infrared spectroscopy study. PLoS One3(3), e1760 (2008).
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS. Cellular and circuit basis of working memory in prefrontal cortex of nonhuman primates. Prog. Brain Res.85, 325–335 (1990).
   PubMed Web of Science ®Google Scholar
• Christian BT, Lehrer DS, Shi B et al. Measuring dopamine neuromodulation in the thalamus: using [F-18]fallypride PET to study dopamine release during a spatial attention task. Neuroimage31, 139–152 (2006).
   PubMed Web of Science ®Google Scholar
• Lehrer DS, Christian BT, Mantil J et al. Thalamic and prefrontal FDG uptake in never medicated patients with schizophrenia. Am. J. Psychiatry162(5), 931–938 (2005).
   PubMed Web of Science ®Google Scholar
• Parellada E, Lomena F, Font M et al. Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic–auditory activation. Nucl. Med. Commun.29(10), 894–900 (2008).
   PubMedGoogle Scholar
• Takahashi H, Kato M, Hayashi M et al. Memory and frontal lobe functions; possible relations with dopamine D2 receptors in the hippocampus. Neuroimage34, 1643–1649 (2007).
   PubMed Web of Science ®Google Scholar
• Rowland LM, Shadmehr R, Kravitz D, Holcomb HH. Sequential neural changes during motor learning in schizophrenia. Psychiatry Res.163(1), 1–12 (2008).
   PubMedGoogle Scholar
• Ko JH, Ptito A, Monchi O et al. Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: a [11C]FLB 457 PET study. Neuroimage46(2), 516–521 (2009).
   PubMed Web of Science ®Google Scholar
• Fernandez-Egea E, Parellada E, Lomeña F et al. A continuous emotional task activates the left amygdala in healthy volunteers: (18)FDG PET study. Psychiatry Res.171(3), 199–206 (2009).
   PubMedGoogle Scholar
• Sabri O, Owega A, Schreckenberger M et al. A truly simultaneous combination of functional transcranial Doppler sonography and H(2)(15)O PET adds fundamental new information on differences in cognitive activation between schizophrenics and healthy control subjects. J. Nucl. Med.44(5), 671–681 (2003).
   PubMedGoogle Scholar
• Niendam TA, Bearden CE, Johnson JK et al. Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr. Res.84(1), 100–111 (2006).
   PubMed Web of Science ®Google Scholar
• Brewer WJ, Yücel M, Harrison BJ et al. Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust. N Z J. Psychiatry.41(2), 129–135 (2007).
   PubMed Web of Science ®Google Scholar
• Stroop R. Studies of interference in serial verbal reactions. J. Exp. Psychol.18, 643–662 (1935).
   Google Scholar
• Kim JJ, Park HJ, Jung YC et al. Evaluative processing of ambivalent stimuli in patients with schizophrenia and depression: a [15O] H2O PET study. J. Int. Neuropsychol. Soc.15(6), 990–1001 (2009).
   PubMedGoogle Scholar
• Maher BA. A tentative theory of schizophrenic utterance. Prog. Exp. Pers. Res.12, 1–52 (1983).
   PubMedGoogle Scholar
• Fernandez-Egea E, Parellada E, Lomeña F et al.18FDG PET study of amygdalar activity during facial emotion recognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.260(1), 69–76 (2010).
   PubMedGoogle Scholar
• Aalto S, Brück A, Laine M, Någren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J. Neurosci.25(10), 2471–2477 (2005).
   PubMed Web of Science ®Google Scholar
• Hill SK, Harris MS, Herbener ES, Pavuluri M, Sweeney JA. Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr. Bull.34(4), 743–759 (2008).
   PubMed Web of Science ®Google Scholar
• Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry.156, 1358–1366 (1999).
   PubMed Web of Science ®Google Scholar
• Gur RE, Calkins ME, Gur RC et al. The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr. Bull.33(1), 49–68 (2007).
   PubMed Web of Science ®Google Scholar
• Aukes MF, Alizadeh BZ, Sitskoorn MM, Kemner C, Ophoff RA, Kahn RS. Genetic overlap among intelligence and other candidate endophenotypes for schizophrenia. Biol. Psychiatry65, 527–534 (2009).
   PubMedGoogle Scholar
• Slifstein M, Kolachana B, Simpson EH et al.COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol. Psychiatry13(8), 821–827 (2008).
   PubMed Web of Science ®Google Scholar
• Bertolino A, Taurisano P, Pisciotta NM et al. Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One5(2), e9348 (2010).
   PubMed Web of Science ®Google Scholar
• Ho BC, Wassink TH, O’Leary DS, Sheffield VC, Andreasen NC. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol. Psychiatry.10(3), 229, 287–298 (2005).
   Web of Science ®Google Scholar
• Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. N Y Acad. Sci.1003, 138–158 (2003).
   PubMed Web of Science ®Google Scholar
• Brewer WJ, Wood SJ, Phillips LJ et al. Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr. Bull.32(3), 538–555 (2006).
   PubMed Web of Science ®Google Scholar
• Hirvonen J, van Erp TG, Huttunen J et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiatry62(4), 371–378 (2005).
   PubMed Web of Science ®Google Scholar
• Lee KJ, Lee JS, Kim SJ et al. Loss of asymmetry in D2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr. Scand.118(3), 200–208 (2008).
   PubMed Web of Science ®Google Scholar
• Brunelin J, d’Amato T, Van Os J, Costes N, Suaud Chagny MF, Saoud M. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res.181(2), 130–135 (2010).
   PubMed Web of Science ®Google Scholar
• Huttunen J, Heinimaa M, Svirskis T et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol. Psychiatry.63(1), 114–117 (2008).
   PubMed Web of Science ®Google Scholar
• Reimold M, Solbach C, Noda S et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl.)190(2), 241–249 (2007).
   PubMed Web of Science ®Google Scholar
• Puri BK. Drugs in Psychiatry. Oxford University Press, Oxford, UK (2006).
   Google Scholar
• Gjedde A, Reith J, Dyve S et al. Dopa decarboxylase activity of the living human brain. Proc. Natl Acad. Sci. USA88(7), 2721–2725 (1991).
   PubMed Web of Science ®Google Scholar
• Ito H, Takano H, Takahashi H et al. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[β-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J. Neurosci.29(43), 13730–13734 (2009).
   PubMed Web of Science ®Google Scholar
• Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry.164(9), 1411–1417 (2007).
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Slifstein M, Frankle WG et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology.33(13), 3111–31125 (2008).
   PubMed Web of Science ®Google Scholar
• Gründer G, Fellows C, Janouschek H et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am. J. Psychiatry.165(8), 988–995 (2008).
   PubMed Web of Science ®Google Scholar
• Nikisch G, Baumann P, Kießling B et al. Relationship between dopamine D(2) receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. J. Psychiatr. Res.44(12), 754–759 (2010).
   PubMedGoogle Scholar
• Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry49(7), 538–544 (1992).
   PubMed Web of Science ®Google Scholar
• Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentrations: a PET study of schizophrenic patients. Am. J. Psychiatry152(10), 1444–1449 (1995).
   PubMed Web of Science ®Google Scholar
• Vernaleken I, Fellows C, Janouschek H et al. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J. Clin. Psychopharmacol.28(6), 608–617 (2008).
   PubMed Web of Science ®Google Scholar
• Arakawa R, Ito H, Takano A et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl.)197(2), 229–235 (2008).
   PubMed Web of Science ®Google Scholar
• Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL. Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology34(13), 2675–2690 (2009).
   PubMedGoogle Scholar
• Mizrahi R, Rusjan P, Agid O et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am. J. Psychiatry164(4), 630–637 (2007).
   PubMed Web of Science ®Google Scholar
• Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs – an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr. Bull.35(4), 789–797 (2009).
   PubMedGoogle Scholar
• Levant B. Novel drug interactions at D2 dopamine receptors: modulation of [3H]quinpirole binding by monoamine oxidase inhibitors. Life Sci.71(23), 2691–2700 (2002).
   PubMed Web of Science ®Google Scholar
• Vyas NS, Patel NH, Nijran KS, Al-Nahhas A, Puri BK. Insights into schizophrenia using positron emission tomography: building the evidence and refining the focus. Br. J. Psychiatry.197(1), 3–4 (2010).
   PubMedGoogle Scholar
• Lucatelli C, Honer M, Salazar JF, Ross TL, Schubiger PA, Ametamey SM. Synthesis, radiolabeling, in vitro and in vivo evaluation of [18F]-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5. Nucl. Med. Biol.36(6), 613–622 (2009).
   PubMedGoogle Scholar